From our 2021 West Oncology Conference, we bring you a session on EGFR Mutation Therapy Resistance and ADCs and TROP2 by Dr. Shayma Kazmi. The learning objectives of her presentation include, to review the current treatment options for patients with EGFR-mutation–positive NSCLC and resultant therapy resistance, discuss ADCs and their evolving role in patients with EGFR-resistant NSCLC, and explore the new transmembrane marker, TROP2, its role in tumorigenesis, and potential targeted agents to inhibit its effects in patients with NSCLC.

To obtain CME/CE credits and MOC points you must participate in the full 2021 West Oncology conference, click here to view all sessions: [ Ссылка ]

Information on obtaining CME/CE Credits and MOC points can be found in the playlist description.

свернуть